A study published in Surgical Endoscopy reported pharmaceutical company Mauna Kea's Cellvizio can aid physicians in Barrett's Esophagus detection.
Researchers conducted an eight-center study on how Cellvizio aided in Barrett's Esophagus detection, recruiting 172 patients. Researchers compared confocal laser endomicroscopy with conventional histology to the Seattle Protocol.
Here's what they found:
1. Novice probe-based confocal laser endomicroscopy doubled the identification rate of Barrett's Esophagus (99) over the Seattle Protocol (46).
2. Cellvizio and biopsies confirmed Barrett's Esophagus was detected by Cellvizio in 56 of 61 patients with negative biopsies.
3. Researchers found no statistically significant difference between novice pCLE users and expert review.
4. Mauna Kea CEO and Co-Founder Sacha Loiseau, PhD, said, "The study demonstrates the broad applicability of pCLE for routine esophageal surveillance. This publication establishes further validation to Cellvizio's superior sensitivity in the detection of Barrett's Esophagus compared to standard protocol and provides a major advancement towards more accurate identification of individuals at risk for esophageal adenocarcinoma."